Salts of 3-pentylphenylacetic acid and pharmaceutical uses thereof

1. A salt represented by the formula:

wherein X + is a base addition salt.

2. The salt, according to claim 1 , in which the base addition salt is sodium, potassium, or lithium.

3. The salt, according to claim 1 , in which X + is sodium.

4. A salt represented by the formula:

5. A pharmaceutical composition comprising a salt of claim 4 , and a pharmaceutically acceptable vehicle.

6. A method of manufacturing a pharmaceutical composition, the method comprising: mixing a salt of claim 4 with a pharmaceutically acceptable vehicle so as to produce the pharmaceutical composition.

7. A method of preventing and/or treating a condition selected from the group consisting of (i) blood disorders (ii) renal disorders and/or renal disorder complications; (iii) inflammatory-related diseases; and (iv) oxidative stress related disorders, said method comprising administering to a human patient in need thereof a pharmacologically effective amount of a salt of claim 4 .

8. A process for preparing the sodium salt of 3-pentylphenylacetic acid, the process comprising:

a) heating a mixture of ethyl [3-bromophenyl]acetate and 1-pentyne in the presence of tetrabutylammonium fluoride hydrate and PdCI 2 (PPh 3 ) 2 to provide ethyl [3-[pentyne-1-yl]phenyl]-acetate;

b) reducing the ethyl [3-[pentyne-1-yl]phenyl]acetate to provide ethyl [3-[pentyl-1-yl]phenyl]acetate; and

c) hydrolyzing ethyl [3-[pentyl-1-yl]phenyl]acetate so as to produce the sodium salt of 3-pentylphenylacetic acid.

9. The process, according to claim 8 , in which the heating step a) is carried out in a sealed tube.

10. The process, according to claim 9 , in which the tube is heated at 80° C. for 2 h.

11. A method for preventing and/or treating a blood disorder in a subject in need thereof, comprising administering to said subject an effective amount of a salt according to claim 1 .

12. The method of claim 11 , wherein the blood disorder is anemia or neutropenia.

13. The method of claim 11 , wherein administration of said composition stimulates hematopoiesis and/or erythropoiesis in the subject.

14. A method for preventing and/or treating a renal disorder and/or a renal disorder complication in a subject in need thereof, comprising administering to said subject an effective amount of a salt according to claim 1 .

15. The method of claim 14 , wherein the renal disorder is nephropathy.

16. The method of claim 14 , wherein the salt is administered for nephroprotection against toxic effects arising from a treatment with a chemotherapeutic agent.

17. The method of claim 16 , wherein clearance of creatinine and/or clearance of uric acid is improved in the subject subsequent to said administration.

18. A method for improving kidney function in a human subject in need thereof, comprising administering to said subject an effective amount of a salt according to claim 1 .

19. The method according to claim 11 , wherein said salt is

20. A method for preventing and/or treating an inflammatory-related disease in a subject in need thereof, comprising administering to said subject an effective amount of a salt according to claim 1 .

21. The method of claim 20 , wherein the inflammatory-related disease is an immune mediated inflammatory disease or an autoimmune disease.

22. The method of claim 21 , wherein the inflammatory-related disease is selected from the group consisting of arthritis, erythematosus (SLE), idiopathic thrombocytopenic purpura (ITP), glomerulonephritis, vasculitis, psoriatic arthritis, psoriasis, Crohn's disease, inflammatory bowel disease, ankylosing spondylitis, Sjogren's syndrome, Still's disease, uveitis, scleroderma, myositis, Reiter's syndrome, and Wegener's syndrome.

23. A method for nephroprotection against toxic effects arising from a treatment with a chemotherapeutic agent in a subject, comprising administering to said subject an effective amount of a pharmaceutical composition according to claim 5 before and/or following treatment with the chemotherapeutic agent.

24. A method for preventing and/or treating an oxidative stress related disorder in a subject in need thereof, comprising administering to said subject an effective amount of a salt according to claim 1 .

25. The method of claim 24 , wherein the oxidative stress related disorder is selected from the group consisting of cardiovascular diseases, cancer, diabetes, arthritis, atherosclerosis, Parkinson's disease, heart failure, myocardial infarction, Alzheimer's disease, chronic fatigue syndrome and autoimmune diseases.